Semaglutide protects diabetic kidneys by activating β-Klotho to inhibit ferroptosis via cAMP-PKA-CREB signaling | Research

The takeaway

Semaglutide alleviates diabetic kidney disease by upregulating β-Klotho through cAMP-PKA-CREB signaling, which activates AMPK to inhibit ferroptosis (iron-dependent cell death), reducing renal inflammation and fibrosis.

Ferroptosis inhibition = kidney protection
Semaglutide activates β-Klotho via cAMP signaling to suppress iron-dependent cell death in diabetic kidneys—a precise, targetable molecular mechanism

What the researchers found

Semaglutide → cAMP-PKA-CREB → ↑KLB (β-Klotho) → AMPK activation → ↓ferroptosis (↓iron, ↓fatty acid synthesis, ↑antioxidant). Result: ↓renal inflammation, ↓fibrosis. Validated in patients, animals, HK-2 cells. KLB identified by transcriptome sequencing.

Why it matters

DKD is the leading cause of end-stage kidney failure. Identifying the exact molecular pathway (cAMP→KLB→AMPK→anti-ferroptosis) by which semaglutide protects kidneys enables targeted therapeutic optimization.

How the study worked

Transcriptome sequencing for target identification. DKD patient samples, animal models, HK-2 kidney cells. cAMP-PKA-CREB pathway analysis. AMPK signaling. Ferroptosis markers (iron, lipid peroxidation, antioxidant).

What this study cannot tell us

Complex pathway—causation at each step needs further validation. KLB upregulation mechanism via cAMP is novel and needs independent confirmation. HK-2 cells may not fully represent in vivo kidney tubules.

How to read the evidence

Multi-level study (transcriptomics, patients, animals, cells). Strong mechanistic evidence with clinical validation.

When this study was published

Published in 2025.

The bigger picture

Ferroptosis is increasingly recognized as a driver of organ damage in diabetes. Semaglutide's ability to suppress it through KLB provides a precise molecular target for renal protection and potentially for other organs affected by ferroptosis.

Questions still open

Could KLB-targeted drugs replicate semaglutide's renal protection?
Is ferroptosis inhibition the key to preventing all diabetic organ damage?
Would ferroptosis markers serve as clinical biomarkers for DKD treatment response?

Common questions

How does semaglutide protect the kidneys?

This study identified the complete molecular chain: semaglutide activates cAMP signaling → which increases β-Klotho protein → which activates AMPK → which stops ferroptosis (a type of iron-dependent cell death that damages kidneys). By stopping ferroptosis, kidney inflammation and scarring are reduced.

What is ferroptosis?

Ferroptosis is a recently discovered form of cell death driven by iron accumulation and lipid damage. It is increasingly recognized as a key driver of kidney damage in diabetes. By blocking ferroptosis through β-Klotho activation, semaglutide protects kidney cells from this destructive process.

Read the original research

GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.

Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(4), e2409781

View on PubMed ↗Publisher’s paper ↗

Citation

Tian, Shasha; Zhou, Saijun; Wu, Weixi; Lin, Yao; Wang, Tongdan; Sun, Haizhen; A-Ni-Wan, A-Shan-Jiang; Li, Yaru; Wang, Chongyang; Li, Xiaogang; Yu, Pei; Zhao, Yanjun. (2025). GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(4), e2409781. https://doi.org/10.1002/advs.202409781